Multiple Sclerosis Therapies Market Revenue Will Increase at $28.00 Billion Globally by 2026, Says AMR

The global multiple sclerosis (MS) therapies market was valued at $22.99 billion in 2018, and is projected to reach $28.00 billion by 2026, registering a CAGR of 2.5% from 2019 to 2026.

The study analyzes the important strategies, drivers, competition, market dynamics, size, and important investment regions.

Key Takeaways:

Growing Prevalence of Multiple Sclerosis: The market for MS therapies has been driven by the increasing prevalence of multiple sclerosis worldwide. MS is a chronic autoimmune disorder affecting the central nervous system, and its prevalence has been on the rise in recent years.

Diverse Treatment Landscape: The market offers a diverse range of treatment options, including disease-modifying therapies (DMTs) that aim to slow down disease progression and manage symptoms. These therapies include injectable, oral, and infusion-based medications, providing patients and healthcare providers with various choices.

Shift Towards Personalized Medicine: With advancements in medical research and technology, there has been a move toward personalized medicine in the MS therapies market. Treatment decisions are increasingly based on individual patient characteristics, such as disease subtype, severity, and genetic makeup, to optimize efficacy and minimize side effects.

Emergence of Novel Therapies: The MS therapies market has witnessed the introduction of several novel therapies and treatment approaches. These include monoclonal antibodies, oral medications, and innovative delivery methods that offer improved convenience and potentially better outcomes for patients.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/1438

Covid-19 Scenario-

• According to the National MS society’s National Medical Advisory Committee, the decisions regarding disease modifying therapies should be collaboratively taken between the person with MS and his healthcare provider during the COVID-19 pandemic.
• On the basis of their expert advice the society recommends that people with MS should follow CDC guidelines along with additional information for people at risk for serious illness from COVID 19. People with MS should continue DMTs and discuss precise risks with their MS healthcare provider before stopping a DMT.
• On the other hand, the pharmaceutical providers all over the world are tackling the situation in terms of production to meet essential requirements. Moreover, the medicinal and other requirement for therapies may witnessed either shortage or delay due to disruption in the supply chain.

Market Drivers:

Rising Prevalence of Multiple Sclerosis: The increasing incidence and prevalence of multiple sclerosis worldwide are significant drivers of the market. As more people are diagnosed with MS, there is a growing demand for effective therapies to manage the disease and improve patients’ quality of life.

Advancements in Medical Research: Ongoing research efforts have led to a deeper understanding of the underlying mechanisms of multiple sclerosis. This has resulted in the development of innovative therapies that target specific pathways involved in the disease, leading to more effective treatment options.

Market Segmentation:

Treatment Type:

• Disease-Modifying Therapies (DMTs): These are the primary treatment options for MS. They aim to modify the course of the disease, reduce relapses, and slow down disease progression.
  • Injectable DMTs (interferons, glatiramer acetate)
  • Oral DMTs (fingolimod, dimethyl fumarate, siponimod)
  • Infusion DMTs (ocrelizumab, natalizumab, alemtuzumab)
• Symptomatic Therapies: These address specific symptoms of MS, such as pain, fatigue, spasticity, and cognitive impairments.

Disease Subtype:

• Relapsing-Remitting MS (RRMS): Most common subtype, characterized by relapses (flare-ups) followed by periods of remission.
• Primary Progressive MS (PPMS): Characterized by gradual worsening of symptoms without distinct relapses.

Route of Administration:

• Injectable: Therapies administered through injections, either subcutaneous or intramuscular.
• Oral: Medications taken orally, in the form of pills or capsules.
• Infusion: Therapies administered through intravenous infusions.

Geography:

• Regional Market Segmentation: Dividing the market based on geographic regions, considering variations in disease prevalence, healthcare infrastructure, and regulatory frameworks.

Request for Customization – 

https://www.alliedmarketresearch.com/request-for-customization/1438

Regional Growth Dynamics:

North America, accounted for the highest share based on revenue, holding for nearly two-fifths of the total share of the global multiple sclerosis therapies market in 2018, owing to rise in U.S. FDA approvals for medications used in the treatment of MS and improved healthcare system in this region. However, LAMEA is estimated to portray the fastest CAGR of 3.1% from 2019 to 2026, owing to the high prevalence of MS in the Middle East countries.

Leading market players-

• Bayer AG
• Biogen
• Bristol-Myers Squibb Company
• ABBVIE INC.
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• SANOFI
• Teva Pharmaceutical Industries Ltd.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/1438

𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲:

Protein Therapeutics Market

Cord Blood Banking Services Market

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape

𝐀𝐛𝐨𝐮𝐭 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting.

Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

David Correa

5933 NE Win Sivers Drive

205, Portland, OR 97220

United States

Toll Free: +1-800-792-5285

UK: +44-845-528-1300

Hong Kong: +852-301-84916

help@alliedmarketresearch.com